Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More

On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. MTTR already moving too much, "I’m going to have to take a big pass."

When asked about Oscar Health, Inc. OSCR, Cramer said, "We’ve got enough health insurance companies…I know that sounds callous, but we don’t need these guys."

The "Mad Money" host said Lemonade, Inc. LMND is a "great company, not a great stock."

Cramer said his charitable trust sold Bristol-Myers Squibb Company BMY around 10 points ago, when the stock was at 2.8% dividend yield. He recommends not selling the stock at 3.59% yield.

The "Mad Money" host said Bionano Genomics, Inc. BNGO is a good spec, but he actually likes CRISPR Therapeutics AG CRSP.

Cramer recommends buying Chegg, Inc. CHGG, as he believes the stock has "come down enough."